Nanozyme-based delivery systems show theoretical antibacterial mechanisms for osteomyelitis treatment

A systematic review examined the therapeutic prospects of nanozyme-based delivery systems for treating osteomyelitis. The review focused on preclinical and theoretical evidence, with no reported clinical trial data, patient population details, sample size, or comparator information. The analysis was limited to potential mechanisms rather than clinical outcomes.

The review identified that nanozymes possess enzyme-mimicking activities, primarily peroxidase-, oxidase-, haloperoxidase-, and hydrolase-like functionalities. These nanozymes can generate reactive oxygen species by catalyzing endogenous hydrogen peroxide and can physically degrade biofilm components. No quantitative effect sizes, absolute numbers, or statistical measures were reported for these mechanisms.

No safety, tolerability, or adverse event data were reported. The review acknowledges this as theoretical/preclinical evidence only, with no clinical efficacy, safety profile, comparative effectiveness, or patient outcome data available. Key limitations include the absence of clinical trial evidence and the purely mechanistic focus of the analysis.

For clinical practice, this review highlights emerging research directions but provides no evidence to support current clinical use. The findings represent early-stage investigation into potential antibacterial mechanisms that require extensive preclinical and clinical validation before any clinical application can be considered.